MethylGene Gets Beta-Lactamase Inhibitor Program Back From Merck
This article was originally published in The Pink Sheet Daily
Executive Summary
Other companies have expressed interest in the antibiotic resistance program, MethylGene CEO tells “The Pink Sheet” DAILY.